title: Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients.
abstract: BACKGROUND
  Smoking cessation interventions in outpatient settings have been demonstrated to be cost effective. Given this evidence, we aimed to evaluate the effectiveness of varenicline tartrate plus Quitline-counselling compared with Quitline-counselling alone when initiated in the inpatient setting.
  
  
  METHODS
  Adult patients (18-75 years) admitted with a smoking-related illness to three hospitals, were randomised to receive either 12-weeks of varenicline tartrate plus Quitline-counselling, (n=196) or Quitline-counselling alone, (n=196), with 12-months follow-up.
  
  
  RESULTS
  For the primary analysis population (intention-to-treat), the proportion of subjects who remained continuously abstinent were significantly greater in the varenicline plus counselling arm (31.1%, n=61) compared with counselling alone (21.4%, n=42; RR 1.45, 95% CI 1.03 to 2.03, p=0.03).
  
  
  CONCLUSIONS
  The combined use of varenicline plus counselling when initiated in the inpatient setting has produced a sustained smoking cessation benefit at 12-months follow-up, indicating a successful opportunistic treatment for smokers admitted with smoking related illnesses.
  
  
  BACKGROUND
  http://www.clinicaltrials.gov/ ClinicalTrials.gov identification number: NCT01141855.
authors.affiliation: Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
authors.forename: Brian James
authors.initials: BJ
authors.lastname: Smith
authors.forename: Kristin Veronica
authors.initials: KV
authors.lastname: Carson
authors.forename: Malcolm Philip
authors.initials: MP
authors.lastname: Brinn
authors.forename: Nadina Ann
authors.initials: NA
authors.lastname: Labiszewski
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Peters
authors.forename: Robert
authors.initials: R
authors.lastname: Fitridge
authors.forename: Simon A
authors.initials: SA
authors.lastname: Koblar
authors.forename: Jim
authors.initials: J
authors.lastname: Jannes
authors.forename: Antony J
authors.initials: AJ
authors.lastname: Veale
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Goldsworthy
authors.forename: John
authors.initials: J
authors.lastname: Litt
authors.forename: David
authors.initials: D
authors.lastname: Edwards
authors.forename: Adrian Jeffrey
authors.initials: AJ
authors.lastname: Esterman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001315:Australia / Q000453:epidemiology; D001552:Benzazepines / Q000494:pharmacology*; D003376:Counseling / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology*; D012907:Smoking / Q000009:adverse effects* / Q000453:epidemiology; D016540:Smoking Cessation / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome; D000068580:Varenicline; D055815:Young Adult
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline